| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
The principal investigators found that the majority of the etiology of the designated intractable pustular psoriasis (generalized) (GPP) was IL-36 receptor antagonist (IL-36Ra) deficiency (DITRA). We investigate the pathophysiology of various skin disorders in DITRA. The purpose of this studies are follows; (1) to analyzed therapeutic effect of DITRA of neutrophil extracellular traps (NETs) inhibitors on GPP model (2) to elulcidate pathophysiology of exacerbation of contact dermatitis due to IL-36Ra deficiency (3) to elucidate pathphysiology of prolong the healing of skin ulcers due to IL-36Ra deficiency. As a result of the research, NETs have been shown to be new therapeutic targets in DITRA. It was revealed that IL-36Ra deficiency can be an exacerbating factor for contact dermatitis and wound healing. Furthermore, it was suggested that inhibition of TLR4 signal by TAK-242 may be a new therapeutic agent for contact dermatitis and wound healing.
|
